

New Zealand standardised oral formulation batch sheet

Ursodeoxycholic acid suspension 50 mg/mL (100 mL)											
Patient's name			Storage condition		In a refrigerator			At room temperature			
NHI				Temperature		2-8°C		≤ 25°C			
Date compounded				Shelf life		30 days		30 days			
Batch number				Recommended storage		V		May be stored at room temperature if this is more practical and temperatures greater than 25°C are avoided			
Ingredients required a	Ingredients required and formula:										
Ingredient	Supplier	Batch number	Expiry date	Star forn			Di by	ispensed /	Checked by		
Ursodeoxycholic acid 250 mg capsules				ca	20 apsules						
Ora-Blend®	Perrigo			to :	100 mL						
OR		I.									
Ora-Plus®	Perrigo				50 mL						
Ora-Sweet®	Perrigo				50 mL						
Ora-Blend SF® or Ora-S	Sweet SF® (sug	gar free) can l	be substituted	? '	Yes						
Calculations performed		•									
Calculations checked by (pharmacist)											
Area cleared for proce	ssing by										
Instructions to compound suspension:											
1. If Ora-Blend® unavailable: Pre-mix the Ora-Plus® and Ora-Sweet® to form the diluent.											
2. Empty the contents of the capsules in a mortar.											
3. Add diluent (Ora-Blend® or prepared diluent) to form a smooth paste.											
4. Gradually add the diluent and transfer to the final measuring flask, rinsing the mortar well. Mix well.											
5. Make up to the final volume and mix well.											
6. Label and pack	kage product a	ppropriately.									
Labels											
Attach product label a						Label	checked by				



New Zealand standardised oral formulation batch sheet

Ursodeoxycholic acid suspension 50 mg/mL (100 mL)

Final yield		mL		Checked by						
Final appearance of product		Pale white suspension.								
Container		Amber plastic mission bottle.								
Compounded by		Name:	Signature:		Date:					
Final check and product re	elease	Name:	Sig	nature:	Date:					
Special instructions:										
1. Shake well before use.										
2. Store in a refrigerator.										
References:										
 Johnson CE, Streetman DD. Am J Health Syst Pharm, 2002; 59(4): 361-3. Allen LV, Jr. Secundum Artem, 2009; 14(3). 										
Prepared by	New Zealand Compounding Working Group									
Approved by	Medication Safety Expert Advisory Group of Health Quality and Safety Commission NZ									
Hosted by	Pharmaceutical Society of New Zealand									
	Standard Formulations in the Practice Support section of the PSNZ website									
Version number	3.0		Version approval date 17/07/19		17/07/19					
Document review due	01/08/21									

Disclaimer: this batch sheet has been designed to provide guidance and standardised formulations for New Zealand pharmacists. Please read and familiarise yourself with the general guidance for compounding oral liquids (available on the PSNZ web site) before use. Information was considered accurate at the time of publication.